Pediatric primary central nervous system tumors registry in Thailand under National Health Security Office schemes

• Main Authors: Bunchoo Pongtanakul, Nongnuch Sirachainan, Pacharapan Surapolchai, Pimlak Charoenkwan, Worawut Choeyprasert, Patcharee Komwilaisak, Su on Chainansamit, Nittaya Witsanuyothin, Yujinda Lertrakul, Piya Rujkijyanont, Somjai Kanjanapongkul, Darintr Sosothikul, Kleebsabai Sanpakit, Thirachit Chotsampancharoen, Somporn Wangruangsathit, Nintita Sripaiboonkij Thokanit, Sommaphun Tabjareon, Suradej Hongeng
• Other Authors: Sappasitthiprasong Hospital
• Format: Article
• Published: 2020
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine; Neuroscience
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/57774
• Institution: Mahidol University

© 2020, Springer Science+Business Media, LLC, part of Springer Nature. Background: Few epidemiological studies of pediatric central nervous system (CNS) tumors have been performed using data from Southeast Asian national registries. Therefore, we aimed to examine data on CNS tumors from the first national childhood CNS tumor registry in Thailand. Methods: Newly diagnosed children with benign and malignant primary CNS tumors from 20 nationwide hospitals were included. Two eras in the Thai registry were studied to compare national protocol effectiveness, including 2003–2005 (before establishment of a pediatric CNS tumor protocol) and 2011–2012 (post-establishment). Results: The first study period had 300 patients with an incidence of 7.5/1,000,000 person-years and the second had 168 patients with an incidence of 13.24/1,000,000 person-years. The three most common tumors were gliomas, medulloblastoma/primitive neuroectodermal tumor (PNET), and germ cell tumors. The most common tumor site was the cerebellum, followed by the brainstem and pineal region. Five- and 10-year overall survival (OS) rates were 46.62% (95% confidence interval [CI] 40.85–52.18) and 41.78% (95% CI 36.11–47.34), respectively, for the first period. The second period had a 5-year OS of 64.75% (95% CI 56.70–71.68). OS rates for gliomas, germ cell tumors, medulloblastoma/PNET, and ependymomas were better in the second period than in the first period. Conclusions: The incidence of primary childhood CNS tumors in our study is lower compared with other reports. Improvement of OS in the second study period might be because of establishment of the Thai Pediatric Oncology Group, and national protocols for childhood CNS tumors.